LOS ANGELES, Oct. 9 Vista Partners announced today that ithas initiated coverage on Raptor Pharmaceuticals Corp.(OTC Bulletin Board: RPTP). "Raptor's management team was pivotal in gettingtwo drugs approved and creating stockholder value while at BioMarinPharmaceutical, a $2.4B biotech company and we believe they will do it againwith Raptor," stated Ross Silver, Director of Research at Vista Partners.Vista Partners provides independent, equity research to institutional andindividual investors, with a focus on publicly traded small capitalizationcompanies. For more information and to download the report; please visit theVista Partners website at http://www.vistap.com.
Raptor Pharmaceuticals Corp.'s (the "Company") sole business is its 100%ownership of Raptor Pharmaceutical Inc., a development stage biotechnologycompany which bioengineers novel drug candidates and drug-targeting platformsderived from the human receptor-associated protein ("RAP") and relatedproteins. The Company's preclinical programs target cancer, neurodegenerativedisorders, infectious diseases and osteoporosis. HepTide(TM) utilizesengineered RAP-based peptides conjugated to drugs to target their delivery tothe liver. In neurodegenerative diseases, engineered RAP peptides calledNeuroTrans(TM) are currently undergoing evaluation at Stanford University incell culture and preclinical models for their ability to enhance the transportof molecules from blood to brain. In osteoporosis, Raptor is testing theability of WntTide(TM), which are Mesd and engineered Mesd-based peptides andact through LRP5, a known determinant of bone density, to combat osteoporosisand increase bone density. In an effort to protect its novel approach, Raptorcurrently has five patent applications in review in the U.S., and countries inEurope and Asia, as well as two provisional patent applications licensed fromWashington University. In addition, the Company has recently submitted two newprovisional patent applications in the U.S., the first of which covers a newfamily of RAP peptides, with the second application to further support andexpand the Company's coverage in specific disease indications.Contact: Vista Partners LLC Ross Silver (415) 738-6229 [email protected]
SOURCE Vista Partners LLC